Repligen | RGEN - Market Capitalization


Repligen reported $9.65B in Market Capitalization this November of 2026, considering the latest stock price and the number of outstanding shares.





Market Capitalization Change Date
Agilent USD 39.08B 6.43B Jun/2026
Align Technology USD 10.33B 1.75B Sep/2026
Bio Techne USD 11.43B 424M Nov/2026
BioMarin Pharmaceutical USD 10.95B 667M Nov/2026
Bristol-Myers Squibb USD 127.46B 9.81B Sep/2026
Bruker USD 9.68B 181M Nov/2026
Charles River Laboratories USD 16.69B 2.7B Nov/2026
Danaher USD 157.81B 18.96B Sep/2026
Dentsply International USD 2.18B 56M Nov/2026
General Electric Aerospace USD 324.02B 65.91B Sep/2026
Henry Schein USD 10.6B 974M Nov/2026
Illumina USD 37.12B 3.64B Nov/2026
IQVIA Holdings USD 48.06B 3.81B Nov/2026
Mettler Toledo International USD 36.36B 10.54B Nov/2026
OraSure Technologies USD 174M 61M Dec/2025
Pacific Biosciences Of California USD 565M 180M Dec/2025
Pfizer USD 169.88B 6.47B Nov/2026
Repligen USD 9.74B 1.1B Nov/2026
Revvity USD 20.19B 3.28B Nov/2026
Standard Biotools USD 227M 95M Nov/2026
Thermo Fisher Scientific USD 249.58B 58.93B Sep/2026
Waters USD 27.23B 14.55B Nov/2026
West Pharmaceutical Services USD 26.09B 730M Sep/2026